New drug SYS6043 targets Hard-to-Treat cancers in early trial

NCT ID NCT07424547

Recruiting now Disease control Sponsor: Conjupro Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early signs that the drug may slow tumor growth. About 386 participants will receive SYS6043 by IV every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYS6043 (a drug given by IV infusion that targets a tumor protein called B7-H3)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early phase 1 trial, so the main goals are safety and dosing — it is too soon to know if SYS6043 will effectively shrink tumors. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer castration-resistant prostate carcinoma metastatic malignant neoplasm neoplasm ovarian cancer prostate cancer small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC CANCER BREAST CANCER CANCER OVARIAN CANCER PROSTATE SMALL CELL LUNG CANCER SOLID TUMOR CANCER

Contacts and locations

Locations

BRCR Global
RECRUITING

Plantation, Florida, 33322, United States
Florida Clinical Trials Group
RECRUITING

Plantation, Florida, 33322, United States
NEXT Oncology Austin
RECRUITING

Austin, Texas, 78758, United States
NEXT Oncology San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.